Fingerprint
Dive into the research topics of 'Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC
Yilin C. Neeley, Kevin T. McDonagh, Willem W. Overwijk, Nicholas P. Restifo, Martin G. Sanda
Research output: Contribution to journal › Article › peer-review
12
Scopus
citations